LIFE: Update on production transfer and longevity programme

As previously communicated, Lifecare has decided to establish manufacturing
operations in Bergen, Norway, as part of the Company's operational
restructuring and centralisation of manufacturing activities. Lifecare is
currently in the operational phase of a production campaign in Cambridge,
executed jointly by Lifecare personnel and the partner's manufacturing team.
The campaign represents the final planned manufacturing activity before
production processes, manufacturing know-how and operational responsibility
are transferred to Lifecare's facilities in Bergen.

The production campaign has three principal objectives:

1.  Complete the transfer of manufacturing processes and know-how from
    Cambridge to Bergen.
2.  Produce implants supporting Lifecare's ongoing regulatory documentation
    and verification activities towards future clinical studies and CE
    marking. Lifecare intends to provide further regulatory update in
    connection with the Q2 report in August. Regulatory preparations continue
    together with external regulatory specialists.
3.  Manufacture implants for the next cohort in the Company's ongoing
    longevity programme in dogs following the summer period.

In the longevity study, the second implant in the current six-month
implantation cohort was explanted yesterday in accordance with study protocol
following six months of continuous implantation under real-life conditions.

Initial post-explantation observations demonstrated continued electronic
functionality, no visible mechanical damage to the implant upon microscopic
inspection, and an apparently intact sensor membrane following retrieval.
Importantly, no clinically significant adverse events, foreign body reactions,
or other observable clinical effects beyond the intended monitoring function
were observed during the six-month implantation period. As with the first
completed six-month implantation, the explanted implant will now undergo
comprehensive laboratory evaluation, including independent histological
assessment of the surrounding tissue.

Throughout the six-month implantation period, study data together with
reference monitoring devices and in-clinic blood glucose assessments provided
the veterinary team with a comprehensive dataset supporting long-term diabetes
management.

Consistent with observations from the first completed six-month implantation,
both the treating veterinarian and the dog's owners reported that continuous
glucose information supported more individualized treatment adjustments and
improved diabetes management throughout the study period, further
strengthening Lifecare's confidence in the potential clinical value of
continuous glucose monitoring in veterinary diabetes care.

The third and final animal in the current six-month cohort is scheduled for
explantation during August.

The ongoing longevity programme continues to generate important information
regarding long-term implant performance, durability, biocompatibility and
overall system functionality, providing valuable input for continued product
optimisation, manufacturing development and regulatory preparations.

Based on experience from the current cohort, Lifecare is implementing further
refinements to the communication architecture of the complete CGM system.
These optimisations do not affect the underlying sensing technology but are
intended to further strengthen overall system robustness as part of the
Company's continuous product development process.

The repeated demonstration of successful six-month implantations from
reproducibly manufactured implants, together with the ongoing transfer of
manufacturing to Bergen, further strengthens Lifecare's transition towards
scalable production and commercialisation, and supports the Company's position
towards potential commercial partners within the veterinary market.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Petter Nielsen, CFO, petter.nielsen@lifecare.no, +47 92 24 74 64
oacim.holter@lifecare.no\, +47 40 05 90 40\
Petter Nielsen\, CFO\, petter.nielsen@lifecare.no\, +47 92 24 74 64\